Michael Galambos, MD
Gastroenterology · Atlanta, GANPI 1356345011
Payments from drug & device makers
Across 531 payments — averaging $3355.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$655K
- Intercept Pharmaceuticals, Inc.$376K
- Pfizer$216K
- Gilead$166K
- AbbVie$105K
- Genentech, Inc.$105K
- plus $159K from 31 others
Across 16 payments — averaging $3140.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$46K
- Celltrion, Inc.$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 50 | $654,576 |
| Intercept Pharmaceuticals, Inc. | 57 | $376,198 |
| Pfizer(2 entities) | 42 | $215,674 |
| Gilead | 43 | $165,870 |
| AbbVie(2 entities) | 160 | $105,156 |
| Genentech, Inc. | 22 | $104,954 |
| Intercept Pharma Europe Ltd. | 6 | $55,191 |
| Novartis | 1 | $48,231 |
| Janssen Research & Development, LLC | 3 | $33,311 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $15,976 |
| Ipsen Pharma SAS | 2 | $4,170 |
| Novo Nordisk AS | 4 | $511 |
| Johnson & Johnson | 18 | $360 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $281 |
| Lilly USA, LLC | 10 | $210 |
| Bristol Myers Squibb | 10 | $158 |
| Boston Scientific | 1 | $145 |
| Ipsen Biopharmaceuticals, Inc | 6 | $119 |
| Astellas Pharma US Inc | 5 | $100 |
| Ironwood Pharmaceuticals, Inc | 7 | $97 |
| UCB, Inc. | 5 | $83 |
| Amgen | 4 | $82 |
| Sanofi | 3 | $60 |
| Intra-sana Laboratories | 2 | $50 |
| Merck | 3 | $50 |
| QOL Medical, LLC | 2 | $49 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Nestle Healthcare Nutrition Inc. | 3 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Shionogi Inc | 2 | $25 |
| Mauna Kea Technologies, Inc. | 1 | $24 |
| Orphalan Inc | 1 | $22 |
| AstraZeneca | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Celltrion USA Inc. | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Organon | 1 | $11 |
How this compares
$1,781,915 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Atlanta
- Douglas WolfAtlanta$6.4M
- Nitin GuptaAtlanta$1.7M
- Heba IskandarAtlanta$978K
- Cynthia RudertAtlanta$720K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Julia LiuAtlanta$412K
- Norman GitlinAtlanta$399K
- Saul KarpenAtlanta$368K
- Roshan ShresthaAtlanta$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.